Secondary malignant neoplasm of bone marrow
ICD-10 C79.52 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of bone marrow.
C79.52 refers to secondary malignant neoplasms that have metastasized to the bone marrow from a primary cancer site. This condition is characterized by the infiltration of malignant cells into the bone marrow, which can disrupt normal hematopoiesis and lead to various complications, including anemia, thrombocytopenia, and leukopenia. The most common primary cancers that metastasize to the bone marrow include breast cancer, prostate cancer, lung cancer, and multiple myeloma. Patients may present with symptoms such as bone pain, fatigue, and signs of systemic illness. Diagnosis typically involves imaging studies, bone marrow biopsy, and laboratory tests to confirm the presence of malignant cells. Staging of the disease is crucial for determining prognosis and treatment options, as well as for palliative care considerations, which may focus on symptom management and quality of life rather than curative intent. Understanding the underlying primary malignancy is essential for comprehensive care and treatment planning.
Detailed history of the primary malignancy, treatment history, and current symptoms.
Patients with known primary cancers presenting with new bone pain or hematologic abnormalities.
Ensure accurate staging and documentation of treatment intent, especially in palliative care settings.
Bone marrow biopsy results, complete blood count (CBC) findings, and treatment response.
Patients with unexplained cytopenias or abnormal blood counts in the context of known malignancies.
Focus on the impact of bone marrow infiltration on blood cell production and related complications.
Used to monitor blood counts in patients with secondary malignancies affecting the bone marrow.
Document the reason for the CBC, including symptoms and history of malignancy.
Oncology and hematology specialists should ensure comprehensive documentation of the patient's cancer history.
Coding C79.52 accurately reflects the presence of metastatic disease in the bone marrow, which is crucial for treatment planning, prognosis, and appropriate reimbursement.
